Top

Published in:

01-08-2010 | PRECLINICAL STUDIES

Purine analogs sensitize the multidrug resistant cell line (NCI-H460/R) to doxorubicin and stimulate the cell growth inhibitory effect of verapamil

Authors: Milica Pešić, Ana Podolski, Ljubiša Rakić, Sabera Ruždijić

Published in: Investigational New Drugs | Issue 4/2010

Summary

The resistant cell line NCI-H460/R and its counterpart NCI-H460 were used to investigate the ability of purine analogs to overcome multidrug resistance (MDR) that seriously limit the efficacy of lung cancer regimens with chemotherapeutic agents. Two purine analogs, sulfinosine (SF) and 8-Cl-cAMP, exerted dose-dependent effects on cell growth in both parental and resistant cell lines. They significantly decreased mdr1 expression in NCI-H460/R cells. Low concentrations (1 µM) of SF and 8-Cl-cAMP in combination with doxorubicin (DOX) exerted synergistic growth inhibition in both cell lines. Pretreatment with SF and 8-Cl-cAMP improved the sensitivity to DOX more than verapamil (VER), the standard modulator of MDR. The increased accumulation of DOX observed after the treatment with SF and 8-Cl-cAMP was consistent with the results obtained with VER. VER stimulated the effect of 8-Cl-cAMP on DOX cytotoxicity and mdr1 expression. Combinations of either SF or 8-Cl-cAMP with VER at clinically acceptable concentrations exhibited synergistic effects on cell growth inhibition in the resistant cell line. SF and 8-Cl-cAMP modulated MDR in NCI-H460/R cells, especially when applied before DOX administration. This feature, together with their ability to reverse MDR, renders the purine analogs (in combination with VER) as potential candidates for improving the clinical activity of existing lung cancer therapeutics.

Yang P, Ebbert JO, Sun Z, Weinshilboum RM (2006) Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review. J Clin Oncol 24:1761–1769CrossRefPubMed

Leonessa F, Clarke R (2003) ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer 10:43–73CrossRefPubMed

Harbottle A, Daly AK, Atherton K, Campbell CF (2001) Role of glutathione-S- transferase P1, P-glycoprotein and multidrug resistance-associated protein 1 in acquired doxorubicin resistance. Int J Cancer 92:777–783CrossRefPubMed

Magnarin M, Morelli M, Rosati A, Bartoli F, Candussio L, Giraldi T et al (2004) Induction of proteins involved in multidrug resistance (P-glycoprotein, MRP1, MRP2, LRP) and of CYP 3A4 by rifampicin in LLC-PK1 cells. Eur J Pharm 483:19–28CrossRef

Uchiyama-Kokubu N, Watanabe T (2001) Establishment and characterization of adriamycin-resistant human colorectal adenocarcinoma HCT-15 cell lines with multidrug resistance. Anti-Cancer Drugs 12:769–779CrossRefPubMed

Pesic M, Markovic JZ, Jankovic D, Kanazir S, Markovic ID, Rakic L, Ruzdijic S (2006) Induced resistance in the human non small cell lung carcinoma (NCI-H460) cell line in vitro by anticancer drugs. J Chemother 18(1):66–73PubMed

Miraglia E, Viarisio D, Riganti C, Costamagna C, Ghigo D, Bosia A (2005) Na+/H + exchanger activity is increased in doxorubicin-resistant human colon cancer cells and its modulation modifies the sensitivity of the cells to doxorubicin. Int J Cancer 115:924–929CrossRefPubMed

Pešić M, Andjelković T, Banković J, Marković ID, Rakić L, Ruždijić S (2009) Sulfinosine enhances doxorubicin efficacy through synergism and by reversing multidrug resistance in the human non-small cell lung carcinoma cell line (NCI-H460/ R). Invest New Drugs 27:99–110CrossRefPubMed

Singh RP, Mallikarjuna GU, Sharma G, Dhanalakshimi S, Tyagi AK, Chan DCF, Agarwal C, Agarwal R (2004) Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor κB-mediated inducibile chemoresistance. Clin Cancer Res 10:8641–8647CrossRefPubMed

10.

Lay JD, Hong CC, Huang JS, Yang YY, Pao CY, Liu CH, Lai YP, Lai GM, Cheng AL, Su IJ, Chuang SE (2007) Sulfasalazine suppresses drug resistance and invasiveness of lung adenocarcinoma cells expressing AXL. Cancer Res 67:3878–3887CrossRefPubMed

11.

Peters GJ, van der Wilt CL, van Moorsel CJ, Kroep JR, Bergman AM, Ackland SP (2000) Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol Ther 87(2–3):227–253CrossRefPubMed

12.

Andjelkovic T, Pesic M, Bankovic J, Tanic N, Markovic ID, Ruzdijic S (2008) Synergistic effects of the purine analog sulfinosine and curcumin on the multidrug resistant human non-small cell lung carcinoma cell line (NCI-H460/R). Cancer Biol Ther 7(7):1024–1032PubMed

13.

Tortora G, di Isernia G, Sandomenico C, Bianco R, Pomatico G, Pepe S, Bianco AR, Ciardiello F (1997) Synergistic inhibition of growth and induction of apoptosis by 8-chloro-cAMP and paclitaxel or cisplatin in human cancer cells. Cancer Res 57:5107–5111PubMed

14.

McDaid HM, Johnston PG (1999) Synergistic interaction between paclitaxel and 8-chloro-adenosine 3′, 5′-monophosphate in human ovarian carcinoma cell lines. Clin Cancer Res 5:215–220PubMed

15.

Srivastava RK, Srivastava AR, Cho-Chung YS (1998) Synergistic effects of 8-chlorocyclic-AMP and retinoic acid on induction of apoptosis in Ewing’s sarcoma CHP-100 cells. Clin Cancer Res 4(3):755–761PubMed

16.

Jankovic D, Pesic M, Markovic J, Kanazir S, Markovic I, Rakic L, Ruzdijic S (2006) The combination of sulfinosine and 8-ClcAMP induces synergistic cell growth inhibition of the human neuroblastoma cell line in vitro. Invest New Drugs 24:15–25CrossRefPubMed

17.

Milosevic J, Kanazir S, Medic-Mijacevic L, Pejanovic V, Stokic Z, Konjevic G, Ruzdijic S (2002) Sulfinosine-induced cell growth inhibition and apoptosis in human lung carcinomas in vitro. Invest New Drugs 20:229–240CrossRefPubMed

18.

Srivastava RK, Srivastava AR, Cho-Chung YS (2000) Synergistic effects of 8-ClcAMP and retinoic acids in the inhibition of growth and induction of apoptosis in ovarian cancer cells: Induction of retinoic acid receptor beta. Mol Cell Biochem 204:1–9CrossRefPubMed

19.

Tortora G, Ciardiello F, Pepe S, Tagliaferri P, Ruggiero A, Bianco C, Guarrasi R, Miki K, Bianco AR (1995) Phase I clinical study with 8-chloro-cAMP and evaluation of immunological effects in cancer patients. Clin Cancer Res 1(4):377–384PubMed

20.

Scala S, Budillon A, Zhan Z, Cho-Chung YS, Jefferson J, Tsokos M, Bates SE (1995) Downregulation of mdr-1 expression by 8-Cl-cAMP in multidrug resistant MCF-7 human breast cancer cells. J Clin Invest 96:1026–1034CrossRefPubMed

21.

Vilpo J, Koski T, Vilpo L (2000) Calcium antagonists potentiate P-glycoproteinindependent anticancer drugs in chronic lymphocytic leukemia cells in vitro. Haematologica 85:806–813PubMed

22.

Revankar GR, Hanna NB, Imamura N, Lewis AF, Larson SB, Finch RA, Avery TL, Robins RK (1990) Synthesis and in vivo antitumor activity of 2-amino-9Hpurine-6-sulfenamide, -sulfinamide, and -sulfonamide and related purine ribonucleosides. J Med Chem 33(1):121–128CrossRefPubMed

23.

Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27–55CrossRefPubMed

24.

Ford JM, Bruggemann EP, Pastan I, Gottesman MM, Hait WN (1990) Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines. Cancer Res 50:1748–1756PubMed

25.

Bösch S, Siavoshian S, Jacquot C, Tomasoni C, Dabouis G, Elanbaloussi Y, Leneel T, More MT, Roussakis C (1997) Correlation between multidrug resistance and the degree of differentiation of non-small-cell bronchopulmonary carcinoma (NSCLC) in vitro and in vivo. Anticancer Res 17(6D):4595–4598PubMed

26.

Wong H, Anderson WD, Cheng T, Riabowol KT (1994) Monitoring mRNA expression by polymerase chain reaction: the “primer-dropping” method. Anal Biochem 223:251–258CrossRefPubMed

27.

Gupte RS, Weng Y, Liu L, Lee MYWT (2005) The second subunit of the replication factor C complex (RFC40) and the regulatory subunit (RIα) of protein kinase A form a protein complex promoting cell survival. Cell Cycle 4:323–329PubMed

28.

Boik JC, Newman RA (2008) A classification model to predict synergism/antagonism of cytotoxic mixtures using protein-drug docking scores. BMC Pharmacol 8:13CrossRefPubMed

29.

Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Marini L, Del Tacca M, Danesi R (2005) Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 68(1):110–118PubMed

30.

Berridge M, Lipp P, Bootman M (1999) Calcium signalling. Curr Biol 9:R157–R159CrossRefPubMed

31.

Trompier D, Chang XB, Barattin R, du Moulinet D’Hardemare A, Di Pietro A, Baubichon-Cortay H (2004) Verapamil and its derivative trigger apoptosis through glutathione extrusion by multidrug resistance protein MRP1. Cancer Res 64:4950–4956CrossRefPubMed

32.

Avery TL, Finch RA, Vasquez KM, Radparvar S, Hanna NB, Revanker GR et al (1990) Chemotherapeutic characterization in mice of 2-amino-9-beta-Dribofuranosylpurine-6-sulfinamide (sulfinosine), a novel purine nucleoside with unique antitumor properties. Cancer Res 50:2625–2630PubMed

Title: Purine analogs sensitize the multidrug resistant cell line (NCI-H460/R) to doxorubicin and stimulate the cell growth inhibitory effect of verapamil
Authors: Milica Pešić
Ana Podolski
Ljubiša Rakić
Sabera Ruždijić
Publication date: 01-08-2010
Publisher: Springer US
Published in: Investigational New Drugs / Issue 4/2010
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-009-9277-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 4/2010

A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors

Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma

MER1, a novel organic arsenic derivative, has potent PML-RARα- independent cytotoxic activity against leukemia cells

Evaluation Of 5-hydroxy-2,3-diaryl (substituted)-cyclopent-2-en-1-ones as cis-restricted analogues of combretastatin A-4 as novel anti angiogenic and anticancer agents

Cytotoxic activities of new iron(III) and nickel(II) chelates of some S-methyl-thiosemicarbazones on K562 and ECV304 cells

Development and pharmacologic characterization of deoxybromophospha sugar derivatives with antileukemic activity

Keynote webinar | Spotlight on antibody–drug conjugates in cancer